Mounjaro HK: how the UK and Hong Kong approaches differ

The myth worth clearing up first: Mounjaro bought abroad counts towards your UK treatment

It's a reasonable assumption. You've been on tirzepatide for a few months in Hong Kong, you feel good, you know your dose, and you'd like to pick up where you left off. The misconception (and it's an understandable one) is that a prescription from one country carries weight with a UK pharmacy. It doesn't, and that's not bureaucracy for its own sake.

UK law requires that prescription-only medicines are dispensed against a valid UK prescription, written by a prescriber registered with the relevant UK body. A Hong Kong prescription isn't a valid UK prescription. More importantly, a UK Independent Prescriber reviewing you as a transfer patient isn't being obstructive; they're doing what the clinical framework asks of them: checking your current weight, your health picture, any relevant changes since your last review, and whether the dose you were on is still appropriate.

At nume, transfer patients are asked to provide evidence of their current treatment before any continuation is considered. That evidence review happens personally, by a GPhC-registered prescriber, on the same day you submit it. It protects you. A prescriber who just takes your word for it and dispenses without looking is the one you should be less comfortable with. You can read more about how our clinical process works on our FAQs page.

How Mounjaro's UK licence compares to what you may have encountered in Hong Kong

Tirzepatide is manufactured by Eli Lilly and sold as Mounjaro in the UK, the US, Hong Kong, and several other markets. The brand name is the same; the regulatory framework is not. In the UK, the MHRA licenses Mounjaro for weight management in adults with a BMI of 30 or above, or 27 and above where at least one weight-related condition is present, hypertension, high cholesterol, obstructive sleep apnoea, prediabetes or type 2 diabetes, among others. NICE's technology appraisal guidance (TA1026) then shapes how the medicine is recommended on the NHS, with stricter eligibility criteria for funded access.

Hong Kong's regulatory body, the Pharmacy and Poisons Board, may have approved tirzepatide under different indications or conditions. Dosing presentations, pen formats, and batch sourcing can all differ by market. This is one reason why medicines sourced from abroad (even genuine product) carry real risks: the supply chain, storage conditions, and lot verification that a UK-licensed pharmacy upholds simply can't be confirmed for medicines bought overseas or via informal channels.

The MHRA has been clear that the only safe route to these medicines is through a UK-registered pharmacy dispensing against a valid prescription. If you're comparing what you've seen in Hong Kong with UK options, our Mounjaro overview covers the UK licence in detail, and our tirzepatide information page sets out the clinical evidence behind it.

What a UK clinical assessment looks at when you've been treated abroad

A UK prescriber reviewing someone who's been on tirzepatide elsewhere will look at broadly the same things they look at for anyone starting or continuing treatment: current BMI, weight history, any conditions that affect eligibility, current medications, and how you've responded to treatment so far. If you've been on 5mg in Hong Kong, that's clinically relevant information, it doesn't mean the UK prescriber will simply continue at that dose, but it does inform their assessment.

The starting dose in the UK is 2.5mg. That first pen exists because titration from a low dose reduces early gastrointestinal side effects; your system adjusts to the medicine before the dose climbs. A prescriber may or may not continue you from where you left off, that's a clinical judgement, not a formality. You can see how the dose schedule works on our 2.5mg page or the 5mg page if you were on that dose.

Our clinical team, led by Mostafa Damghani and fellow GPhC-registered Independent Prescribers, carry out photo-ID verification, live weight checks by video, and a full medication review as standard. That's not extra friction, it's what legitimate clinical oversight looks like. The NICE appraisal of tirzepatide and the NHS patient information on tirzepatide both provide useful background on how the medicine is assessed and monitored in the UK.

Cost, supply chain, and what 'cheaper abroad' actually means

People sometimes ask whether they should stock up on Mounjaro while travelling, or whether a contact in Hong Kong can send them pens. Leaving aside import rules, the supply-chain question is the real one. Genuine Mounjaro requires cold-chain storage: refrigerated at 2–8°C throughout transit. Informal supply from abroad rarely guarantees that, and counterfeit versions of tirzepatide pens do exist, the MHRA raided the first illicit UK site producing fake tirzepatide pens in Northampton in October 2025.

If cost is a factor in why you're looking at overseas sources, it's worth understanding what UK private pricing actually includes. Our Mounjaro prices page covers the context around UK private treatment costs, including what reputable services include in a single price (consultation, prescription, delivery, and aftercare) versus providers who advertise a low headline and charge separately for the rest. The right measure for a prescription medicine isn't the cheapest listing; it's whether the supply is genuine, clinically supervised, and legally dispensed. Those things cost something, and they're worth it.

If you'd like to explore whether UK treatment is suitable for you, our free consultation is the place to start, reviewed the same day by a named prescriber, no waiting list. You can also find out more about e mounjaro and how it fits into the broader range of options we offer.